This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Smouldering myeloma (asymptomatic myeloma)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

smouldering myeloma (asymptomatic myeloma)

Smouldering myeloma is defined as an asymptomatic proliferative disorder of plasma cells (1).

  • resembles MGUS (because end organ damage is absent) but the risk of progression to symptomatic or active multiple myeloma or amyloidosis at 20 years is high (78% probability for smouldering multiple myeloma vs. 21% for MGUS)
  • it is the point of transition from MGUS to myeloma (2)

Diagnostic criteria for smouldering myeloma include:

  • monoclonal protein present in the serum, 3 g per 100 ml or higher
  • monoclonal plasma cells 10% or greater present in the bone marrow and/or a tissue biopsy
  • no evidence of end-organ damage attributable to the clonal plasma cell disorder:
    • normal serum calcium, haemoglobin level and serum creatinine
    • no bone lesions on full skeletal X-ray survey and/or other imaging if performed
    • no clinical or laboratory features of amyloidosis or light chain deposition disease

These patients should not be treated. They should be followed up closely since many develop symptomatic myeloma (4)

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.